Targeted radiation and second-line therapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining a second-line medication with precise radiation (SBRT) for people whose liver cancer has only a few new or growing spots after first treatment. It aims to see if this approach can control cancer better than medication alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to care for yourself and do daily activities (Karnofsky score of 80 or higher).
- You have liver cancer that has progressed in 1 to 5 spots (in up to 3 organs) after your first standard treatment (like bevacizumab plus atezolizumab or lenvatinib).
- These progressive spots are suitable for radiation and each is no larger than 5 cm.
- Your liver function is good (Child-Pugh score 7 or lower).
- Your blood counts and kidney function meet minimum levels (see your doctor for exact numbers).
- You have not had radiation to the same spots before and no major side effects from first treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted radiation therapy (SBRT) to standard systemic therapy helps people with advanced liver cancer live longer compared to systemic therapy alone.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.